Insider Trading March 31, 2026

Daxor CFO Acquires $9,900 in Stock as Company Posts Revenue Gain and Completes $8.1M Offering

Robert J. Michel increases his stake while Daxor reports stronger 2025 operating revenue and a regulatory filing transition in progress

By Caleb Monroe DXR
Daxor CFO Acquires $9,900 in Stock as Company Posts Revenue Gain and Completes $8.1M Offering
DXR

Daxor CORP Chief Financial Officer Robert J. Michel purchased 1,000 shares of company stock for $9.90 per share on March 31, 2026, bringing his direct holding to 21,050 shares. The transaction coincides with a stock price trading below the purchase level, recent operating revenue growth, an increase in net assets and a completed registered direct offering that raised roughly $8.1 million in net proceeds. The company is also pursuing a regulatory reporting change expected by the end of the second quarter.

Key Points

  • CFO Robert J. Michel bought 1,000 shares at $9.90 on March 31, 2026 and now owns 21,050 shares.
  • Daxor reported a 45% increase in operating division revenue for 2025 and net assets rose to $45.9 million as of December 31, 2025.
  • The company completed a registered direct offering that raised about $8.1 million and is pursuing a change in regulatory reporting to the Securities Exchange Act of 1934.

Chief Financial Officer Robert J. Michel of Daxor CORP (NASDAQ:DXR) reported an insider purchase of 1,000 shares of common stock at $9.90 per share on March 31, 2026, for a total outlay of $9,900. After the acquisition, Michel directly holds 21,050 shares of Daxor stock.

The purchase came while the market price was below the transaction level. Daxor shares were trading at $9.67 at the time noted in reporting, reflecting a year-to-date decline of 34%.

Independent analysis cited in relation to the company indicates a low price-to-earnings multiple, with shares trading at a P/E ratio of 5.41. That same analysis references additional research services available for the ticker that offer further data and suggested reading for investors.

Separately from the insider transaction, Daxor disclosed several financial and operational updates for 2025. The company said an operating division posted a 45% revenue increase in 2025 compared with the prior year. On the balance sheet side, Daxor reported net assets of $45.9 million as of December 31, 2025, up from $35.8 million a year earlier. Net asset value per share rose to $9.07 from $7.25 over the same period.

In regulatory matters, the company has announced plans to move its reporting framework from the Investment Company Act of 1940 to the Securities Exchange Act of 1934. That shift is subject to required approvals and is expected to be completed by the end of the second quarter, a step the company says reflects growth in its diagnostic technology business.

Daxor also completed a registered direct offering of common stock, raising approximately $8.1 million in net proceeds. The offering consisted of 765,958 shares sold at $11.75 per share and was executed under the company’s shelf registration statement.

Taken together, the insider purchase and the company disclosures outline a mix of corporate actions and financial changes: an executive increasing his direct ownership, recent operating revenue growth, a larger net asset base and a capital raise completed through a registered offering, alongside a planned change in regulatory reporting status.


Key points

  • Robert J. Michel purchased 1,000 shares at $9.90 on March 31, 2026, now directly owning 21,050 shares.
  • Daxor reported a 45% year-over-year revenue increase for an operating division in 2025 and net assets of $45.9 million as of December 31, 2025.
  • The company completed a registered direct offering raising about $8.1 million and plans to move reporting from the Investment Company Act of 1940 to the Securities Exchange Act of 1934 pending approvals.

Risks and uncertainties

  • Share price performance: The stock was trading at $9.67 and is down 34% year-to-date, indicating market pressure on the share price.
  • Regulatory transition: The shift in reporting status is subject to required approvals and is not guaranteed to be completed as expected.
  • Capital transactions: The registered direct offering involved the sale of 765,958 shares at $11.75 each, which alters the company’s capitalization and warrants monitoring by investors.

Risks

  • The stock was trading at $9.67 and was down 34% year-to-date, reflecting market weakness.
  • The planned transition from the Investment Company Act of 1940 to the Securities Exchange Act of 1934 depends on obtaining required approvals.
  • The registered direct offering of 765,958 shares at $11.75 per share changes the company’s capital structure and should be monitored by investors.

More from Insider Trading

ArrowMark Financial Director Buys 1,500 Shares as Company Launches Rights Offering Mar 31, 2026 Strawberry Fields REIT Director Acquires $17,465 Stake; Company Announces Dividend and Executive Pay Changes Mar 31, 2026 Edgewise Therapeutics CMO Disposes Shares While Exercising Options Amid Positive Trial News Mar 31, 2026 Platinum Equity Disposes of 1.35M Ingram Micro Shares in $28.8M Trade Mar 31, 2026 Adaptive Biotechnologies President Disposes of $751k in Stock While Exercising Options Mar 31, 2026